Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO THE PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week we’re digging into one of the biggest narratives in biotech over the past cycle: AI-driven drug discovery, and whether it’s actually delivering on its promise or just compressing timelines without improving outcomes. We break down how the original pitch of faster, cheaper, and more successful drug development is now colliding with the reality of clinical biology, where failure rates remain stubbornly high. Along the way, we look at shifting behavior from large pharma partners, the growing gap between platform hype and tangible results, and why the real bottleneck in drug development may never have been discovery in the first place. The core question for this episode: is AI truly changing the game, or just making an already broken system run slightly faster?
📣🎙️ TODAY’S PODCAST:
[ 00:34 ] Billions into AI drug discovery
[ 01:04 ] AI doesn’t cure diseases
[ 01:38 ] Expensive illusion vs reality
[ 02:23 ] Original pitch inefficiency problem
[ 03:48 ] Only 10 percent solved
[ 05:09 ] Clinical trials sobering results
[ 06:45 ] Speed vs success in clinic
[ 08:07 ] Big Pharma deal shift
[ 13:10 ] Valuation bubble and CRO risk
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
